Results 11 to 20 of about 15,755 (201)
CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy
Frontiers in Immunology, 2022 RationaleRecent studies have demonstrated the feasibility of CD38-specific antibody constructs for in vivo imaging of multiple myeloma. However, detecting multiple myeloma in daratumumab-pretreated patients remains difficult due to overlapping binding ...
Luca Julius Pape +14 more
doaj +1 more source
Haematologica, 2020 Intravenous daratumumab is approved for the treatment of multiple myeloma. In Part 1 of the PAVO study, a mix-and-deliver subcutaneous formulation of daratumumab with recombinant human hyaluronidase PH20 (rHuPH20) was well tolerated, with low rates of ...
Jesus San-Miguel +16 more
doaj +1 more source
Experimental Hematology & Oncology, 2018 Background The monoclonal antibody daratumumab, approved for treating myeloma, targets CD38, a protein on myeloma and also on CD34+ hematopoietic progenitor cells.
Xun Ma +13 more
doaj +1 more source
Bone marrow senescence and the microenvironment of hematological malignancies [PDF]
, 2020 Senescence is the irreversible arrest of cell proliferation that has now been shown to play an important role in both health and disease. With increasing age senescent cells accumulate throughout the body, including the bone marrow and this has been ...
Bowles, Kristian M. +3 more
core +1 more source
Therapeutic Advances in Hematology, 2021 Daratumumab is a humanized anti-CD38 IgG1 monoclonal antibody which could be used for multiple myeloma (MM). MM with plasma-cell leukemia (PCL) transformation is highly aggressive and is resistant to conventional therapy.
Chen-lu Yang +4 more
doaj +1 more source
Journal of International Medical Research, 2021 Objective To systematically evaluate the efficacy and safety of combination regimens containing daratumumab in patients with multiple myeloma (MM). Methods A systematic search of publications listed on electronic databases (PubMed®, The Cochrane Library,
Yin Wang, Yanqing Li, Ye Chai
doaj +1 more source
New Methods in Treatment of Renal failure in Patients with Multiple Myeloma: A Review with Immunological Approach. [PDF]
, 2017 Multiple myeloma (MM), as one of a variety of autoimmune diseases, affects the immune system and, on the other hand, is considered to be a hematologic impairment.
Iranparast, Sara. +2 more
core +1 more source
Blood Advances, 2017 : Daratumumab, a human CD38 imunoglobulin G 1κ monoclonal antibody, has demonstrated clinical activity and a manageable safety profile in monotherapy and combination therapy clinical trials in relapsed and/or refractory multiple myeloma.
Tineke Casneuf +13 more
doaj +1 more source
B-cell targeting with anti-CD38 daratumumab: implications for differentiation and memory responses
Life Science Alliance, 2023 Daratumumab is an anti-CD38–targeting antibody that depletes plasma cells. This study shows that daratumumab also disturbs humoral immune responses beyond depletion only and may be used as therapeutic in B cell–mediated autoimmune diseases.
Dorit Verhoeven +5 more
doaj +1 more source
Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma [PDF]
, 2017 New therapeutic strategies are urgently needed to improve clinical outcomes in patients with multiple myeloma (MM). Daratumumab is a first-in-class, CD38 human immunoglobulin G1κ monoclonal antibody approved for treatment of relapsed or refractory MM ...
Ahmadi, Tahamtan +13 more
core +1 more source